Reimbursed Care Access in Seychelles

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Misuse of Drugs Act, 2016 creates heavy penalties for possession, supply and cultivation of Class A/B controlled substances and is the governing statutory framework used to regulate and criminalise the possession and distribution of psilocybin-containing materials in Seychelles. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is controlled under the Misuse of Drugs Act framework and there is no public evidence of an approved clinical or reimbursement pathway for MDMA-assisted therapy in Seychelles. #

There is no publicly-available evidence that esketamine (Spravato®) has been registered by Seychelles regulatory authorities or included on Seychelles’ national medicines lists or reimbursement schedules; therefore it is not an authorised, reimbursed treatment in routine care in Seychelles. Esketamine is a distinct pharmaceutical product from racemic ketamine and, where it is available internationally, is typically governed by specialised regulatory controls and REMS-style programs; no Seychelles-specific approval or reimbursement notices have been located in national documents or the Seychelles essential medicines listing. The Seychelles national Misuse of Drugs Act remains the primary statute for controlled substances and would govern any regulatory pathway for controlled novel agents pending a formal authorisation process. # #

Ketamine is an established, licit medical anaesthetic and analgesic used in Seychelles’ health system and appears on or aligns with medicines commonly found on national essential medicines lists (ketamine is widely included on national essential medicines lists globally and noted in analyses of countries’ lists). Its regulated clinical use for anaesthesia and acute analgesia is standard; supply and prescribing are governed by national medicines regulation and the Misuse of Drugs Act, which controls handling of narcotic/psychotropic substances. # # #

Clinical/medical context and reimbursement nuance:
- Regulatory body and framework: Controlled handling, dispensing and prescribing of ketamine in Seychelles fall under national medicines regulation and the Misuse of Drugs Act, 2016; enforcement and operational drug-control activities are performed by national enforcement agencies (Anti‑Narcotics Bureau / police) in coordination with health authorities. #

- Public vs private coverage and reimbursement: Ketamine’s primary licensed indication (anaesthesia/analgesia) is delivered within public and private surgical and emergency services. There is no publicly-published, nationally-standardised reimbursement schedule for novel ketamine-based psychiatric programmes (e.g., repeat IV ketamine for depression) in Seychelles; psychiatric/off‑label use would therefore typically be delivered out of the standard anaesthesia/acute-care pathway and is not known to be reimbursed as a licensed, routine mental-health intervention. The national essential medicines listing and public health procurement focus on core anaesthetic agents rather than novel psychiatric indications. #

- Indications and off-label psychiatric use: While ketamine is globally studied and sometimes used off-label for treatment‑resistant depression in other jurisdictions, there is no Seychelles-specific regulatory guidance or reimbursement programme for psychiatric ketamine therapy; any off-label psychiatric application would require local institutional approvals and would likely be provided without a formal public reimbursement pathway. Providers would be expected to follow international standards of care and local medical governance when delivering off-label treatments. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (N,N‑dimethyltryptamine) and plant materials containing DMT (e.g., Psychotria, Banisteriopsis species) would fall under the Misuse of Drugs Act controls; there is no authorised medical or reimbursed pathway for DMT therapy in Seychelles. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is a controlled tryptamine and is not known to have any authorised medical or reimbursement status in Seychelles. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of an authorised clinical programme or reimbursement pathway for ibogaine in Seychelles; possession or trafficking would be governed by the Misuse of Drugs Act. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ayahuasca contains DMT and associated plant MAOI components and would be regulated under the Misuse of Drugs Act; there is no legalised ritual or medical exemption for ayahuasca use in Seychelles. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline‑containing cacti such as peyote) are controlled under the national Misuse of Drugs Act and there is no authorised medical or reimbursed therapeutic pathway in Seychelles. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family of phenethylamine psychedelics (e.g., 2C‑B, 2C‑I etc.) are not authorised for therapeutic use in Seychelles and are encompassed by the Misuse of Drugs Act controls and enforcement approach. #